AI주식인사이트AI Stock Insight
B

대웅

003090KOSPI의약품 제조업

56.8 / 100

Reference Date: 2026-04-13

Financial Score27.5 / 40
News Sentiment11.3 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Declined 5.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Dae Woong Co., Ltd., a global healthcare group holding company, reported consolidated sales of 2.684 trillion KRW in 2025, a 6.8% increase from the previous year, though operating profit declined 7.1% to 2.618 billion KRW. Its subsidiary Dae Woong Pharm achieved 13.91 trillion KRW in sales and 2.036 billion KRW in operating profit in 2025, driven by growth in key products like Nabohta and Pexuclo, as well as investments in R&D and digital healthcare initiatives.

Number of Employees

413people

Average Salary

69.2M KRW

Score Calculation Basis

Detailed Financial Score

PER
5.71Industry Average 14.808.0Point

Half of industry avg (excellent)

PBR
0.74Industry Average 1.045.5Point

Lower than industry avg (good)

ROE
13.94Industry Average 4.427.0Point

3.2x industry avg (excellent)

Debt Ratio
39.33Industry Average 11.980.0Point

3.3x industry avg (risky)

Trend 2023~20257.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲6.8% (2-year basis)

Operating Profit Growth Rate
2.5 / 3

Avg ▲18.5% (2-year basis)

ROE Trend
2.5 / 4

Avg ROE 10.9% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 0Neutral 1Negative 0Average Sentiment Score 40

Detailed Momentum

52-week position3.0Point

52w lower range (31%)

Current 22,400Won52-week high 29,35052-week low 19,260
1-month return2.0Point

1m -5.88% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0
  • Neutral투자판단관련주요경영사항(자회사의 주요경영사항)2026-04-10
  • Neutral최대주주등소유주식변동신고서2026-03-26
  • Neutral정기주주총회결과2026-03-26
  • Neutral감사보고서제출(자회사의 주요경영사항)2026-03-23
  • Neutral사업보고서 (2025.12)2026-03-18